(Q38282800)

English

New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

1 reference

Europe PubMed Central

New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

0 references

1 reference

ChEBI release 2020-05-28

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

3

object named as

Naoya Sakamoto

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

author name string

Makoto Chuma

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Katsumi Terashita

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

publication date

4 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Hepatology Research

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

E1-E11

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Epidemiology of viral hepatitis and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Liver resection and transplantation in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Angiogenesis and tumor metastasis

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

What brings pericytes to tumor vessels?

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Raf: a strategic target for therapeutic development against cancer

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Targeting the HGF/c-Met axis: state of play.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Angiogenesis in liver disease

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Novel advancements in the management of hepatocellular carcinoma in 2008.

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12459

21 January 2018

Identifiers

10.1111/HEPR.12459

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38282800&oldid=1751912481"